Immunovia is a diagnostic company that develops high-accuracy blood tests for early detection of cancer and autoimmune diseases, based on the inhouse developed and proprietary test platform: IMMray™.

The breakthrough product, IMMray™ PanCan-d – a blood-based test developed for the unmet need of early and accurate detection of pancreatic cancer (PDAC) – will be commercially launched in the United States in the fourth quarter 2020. This will be followed by a European roll-out of IMMray™ PanCan-d and, subsequently, in other markets.

Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and Lund, Sweden will provide laboratory testing services in two accredited reference laboratories.

Learn more about IMMray™ PanCan-d, IMMray™ platform and Immunovia.

Link to Immunovia’s Virtual Investor Day, June 30 2020

Link to Immunovia company presentation, May 2020

Join us. Join Immunovia WALK for awareness of pancreatic cancer.